Exicure NASDAQ:XCUR Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure's lead program is cavrotolimod (AST-008) which is being evaluated in a Phase1b/2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL.

Location: 8045 Lamon Ave Ste 410, Illinois, 60077-5318, US | Website: www.exicuretx.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services